(PharmaNewsWire.Com, April 26, 2019 ) The "Global Multiple Sclerosis Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of multiple sclerosis therapeutics market with detailed market segmentation by drug class, route of administration, distribution channel and geography. The global multiple sclerosis therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading multiple sclerosis therapeutics market players and offers key trends and opportunities in the market.
The multiple sclerosis therapeutics market is anticipated to grow in the forecast, owing to the factors such as growing research and development for neurology diseases, launch of novel drug candidates and the rising prevalence of multiple sclerosis in children. However, the failure of drugs to prevent disease progression and disability, associated side effects of the drugs such as increased risk of infections, flu-like symptoms and progressive multifocal leukoencephalopathy (PML), are the factors hindering market growth.
Multiple sclerosis (MS) is a potentially disabling disease of the central nervous system. In MS, the patient's body immune system attacks the protective sheath (myelin) affecting the nerve fibers and which further lead to communication problems between the brain and the rest of your body. Eventually, the disease can cause permanent damage or deterioration of the nerves. Some people with severe MS may lose the ability to walk independently or at all, numbness or weakness in limbs and others.
The List of Companies
1. Novartis AG 2. Teva Pharmaceuticals Industries Ltd. 3. Sanofi Genzyme 4. Bayer AG 5. Pfizer, Inc. 6. Biogen Idec 7. Merck and Co., Inc 8. Abbvie, Inc. 9. Alkermes 10. Mapi-pharma Ltd.
The global multiple sclerosis therapeutics market is segmented on the basis of drug class, route of administration, distribution channel and geography. Based on drug class, the market is segmented as immunosuppressant and immunomodulators. On the basis of route of administration, the global multiple sclerosis therapeutics market is segmented into injectable and oral. The distribution channel segment is further segmented into hospital pharmacies, retail pharmacies and e-commerce.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Multiple sclerosis therapeutics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Multiple sclerosis therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Mmultiple sclerosis therapeutics market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Multiple sclerosis therapeutics market in these regions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
